Rapamycin Matches Calorie Restriction — and Starts Working in Hours, Not Months

Rapamycin Matches Calorie Restriction — and Starts Working in Hours, Not Months

When researchers at the University of East Anglia split a middle-aged mouse colony in half — one group on rapamycin-laced chow, the other eating less overall — both stretched their remaining lifespan by 23% in females and 13% in males. Same finish line. Different roads.

That result stunned the field. Calorie restriction has been the gold standard across species for decades. Rapamycin — a compound first scraped from Easter Island soil bacteria in the 1970s — wasn't supposed to tie it. But it did, and with a crucial edge: where dietary restriction took weeks to rev up autophagy (the cellular cleanup process) and metabolic adaptation, rapamycin triggered the same machinery within hours of the first dose. In early human trials, older adults on short courses of rapalogs (rapamycin-related drugs) showed measurable immune improvements. The catch is that long-term human data is thin — researchers still haven't agreed on endpoints like frailty scores that would let them confidently recommend doses outside clinical settings.

The uncomfortable implication: rapamycin appears to work even without the gym or the kale — but the evidence suggests it works significantly better with both.

Gobble's Take: The most powerful anti-aging drug discovered this century was found in dirt on a remote island in 1972 — and your doctor can prescribe it today.

Source: Medical Xpress

The Man Who Trains Tour de France Champions Says the Longevity Industry Is Selling You Anxiety Relief

Inigo San Millán has spent years inside the lungs and legs of Tadej Pogačar, the two-time Tour de France champion. His day job is optimizing human performance at its absolute ceiling. So when he looked at the current longevity menu — plasma exchanges, NAD infusions, senolytic cocktails, photobiomodulation panels — his response wasn't awe. It was skepticism.

San Millán's core argument, laid out in a pointed Substack essay, is that most longevity therapies treat aging like a disease to be hacked, when the data shows it's the accumulated invoice from decades of poor fuel, chronic stress, and sedentary living. His evidence comes from his own athletes: Pogačar's mitochondrial efficiency — the engine's ability to burn fat cleanly at high effort — runs at levels most 30-year-olds can't touch. No infusions. No peptide stacks. Zone 2 cardio, done consistently, for years. San Millán argues that a 45-minute fat-burning jog produces mitochondrial adaptations that no supplement has yet replicated in a head-to-head trial.

That doesn't make senolytics or NAD precursors useless. But San Millán's warning is specific: when a $5,000 drip replaces a training habit rather than supplementing one, you're not extending your life — you're extending your subscription.

Gobble's Take: The guy who built the world's best cyclist says the longevity industry's best product is still a pair of running shoes.

Source: Inigo San Millán Substack

NAD+ Drops 50% by Age 50 — Here's the Cheapest Way to Push Back

Nicotinamide adenine dinucleotide — NAD+, the coenzyme that powers mitochondria, DNA repair, and stem cell maintenance — doesn't fade gracefully. By the time most people hit 50, levels have dropped roughly in half from their peak. The downstream effects read like a checklist of aging itself: chronic inflammation, impaired repair, accumulating senescent cells, metabolic slowdown.

A new review across more than 60 studies maps what actually moves the needle. Oral precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) can raise NAD+ levels measurably in humans, with some trials suggesting downstream improvements in metabolic markers and, in animal models, epigenetic age. But the review flags a persistent problem: oral bioavailability is inconsistent. Much of what you swallow gets metabolized before reaching target tissues, which is why some researchers have moved toward IV delivery — and why the supplement industry is racing toward more stable, better-absorbed formulations. In the meantime, lifestyle inputs matter more than most labels admit: sustained aerobic exercise, intermittent fasting, and diets rich in polyphenols (think blueberries, dark greens) each stimulate NAD+ production through separate pathways, and they stack.

The most expensive NAD+ protocol in the world still gets outperformed by the one your body runs for free — if you give it the inputs.

Gobble's Take: Before the $150 NMN bottle, try the $4 blueberry pint — the pathway is the same, the markup isn't.

Source: ChemRxiv

A Strawberry Compound Is Clearing Zombie Cells as Effectively as Drugs That Cost Thousands

Senescent cells — sometimes called "zombie cells" — are cells that have stopped dividing but refuse to die. They accumulate with age, pumping out inflammatory signals that stiffen tissue, cloud cognition, and accelerate the breakdown of healthy neighbors. Clearing them is one of the most promising targets in longevity research. The question is how.

Fisetin, a flavonoid found in strawberries, is emerging as a surprisingly competitive answer. In recent animal studies, mice treated with fisetin maintained muscle mass and showed strength gains roughly 20% above controls — results that matched synthetic senolytic drugs in head-to-head comparisons, according to a review of current senolytic interventions. The dosing protocol matters: fisetin isn't taken daily. The emerging approach is intermittent — short, concentrated pulses designed to clear zombie cells without disrupting healthy tissue turnover. Human pilot trials testing fisetin and a related compound, quercetin (found in onions and apples), are now underway, targeting mobility, cognitive fog, and epigenetic age markers. Early results are cautious but encouraging.

Pharmaceutical senolytics are coming — several are in clinical pipelines — but the natural versions are clearing animal frailty at a fraction of the cost, and the gap in efficacy has yet to materialize.

Gobble's Take: The anti-aging drug your body actually wants might be sitting in the produce aisle waiting for you to stop scrolling supplement ads.

Sources: Hone Health · PMC · PMC

Quick Hits

• Precision longevity reaches the single-cell level: New research using single-cell sequencing is mapping how aging interventions affect individual cell types differently — meaning the same drug may extend life in one tissue while doing nothing in another, upending the idea of one-size-fits-all protocols. Frontiers in Aging
• 2026 anti-aging therapeutics preview: A new clinical review identifies epigenetic reprogramming, next-generation senolytics, and GLP-1 receptor agonists as the three therapies most likely to move from trial to prescription within the next 18 months. Expert Opinion on Pharmacotherapy

In Case You Missed It

Yesterday's top stories:

• Your Doctor's Next Prescription Might Be "Make a Friend"
• The 2,500-Year-Old Eating Rule That Beats Most Modern Diets
• The Longevity Variable Retirement Planners Never Mention
• 15 Minutes of Walking a Day Reduces Your Risk of Death by 14%